Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics announced the dosing of the first participant in the Phase 1 trial of KT-485, an oral IRAK4 degrader for immuno-inflammatory diseases, conducted by partner Sanofi. This milestone triggered a $20 million payment from Sanofi to Kymera under their collaboration, which includes potential total milestones of up to $975 million. The t…